STOCK MARKET BSE NSE

J&J Booster dose of its COVID shot prompts strong response against virus, says company

J&J said in statement Tuesday that it ran two early studies in people previously given its vaccine and found that a second dose produced an increased antibody response in adults from age 18 to 55.

Published: 21st September 2021 05:02 PM  |   Last Updated: 21st September 2021 06:37 PM   |  A+A-

Representational Image. (Photo | AP)

By PTI

LONDON: Johnson & Johnson released data showing that a booster dose to its one-shot coronavirus vaccine provides a strong immune response months after people receive a first dose.

J&J said in statement Tuesday that it ran two early studies in people previously given its vaccine and found that a second dose produced an increased antibody response in adults from age 18 to 55.

The study's results haven't yet been peer-reviewed.

"A booster dose of the Johnson & Johnson COVID-19 vaccine further increases antibody responses among study participants who had previously received our vaccine," said Dr Mathai Mammen, global head of research and development at J&J.

The company previously published data showing its one-shot dose provided protection for up to eight months after immunization.

J&J said it is now in talks with regulators including the US Food and Drug Administration, the European Medicines Agency and others regarding using booster doses of its vaccine.

J&J's vaccine is approved for use in the US, across Europe and there are plans for at least 200 million doses to be shared with the UN-backed COVAX effort aimed at distributing vaccines to poor countries.

But the company has been plagued by production problems and millions of doses made at a troubled factory in Baltimore had to be thrown out.

The J&J vaccine has been considered critical by numerous health officials to ending the pandemic because it requires only one shot, but fears about the easier-to-spread delta coronavirus variant have prompted numerous governments to consider the use of booster shots for many approved vaccines.

Last week, experts at the FDA recommended people 65 and older get a third dose of the COVID-19 vaccine made by Pfizer-BioNTech while Britain previously authorized booster shots for people 50 and over in addition to priority groups like health workers and those with underlying health conditions.

Other countries including Israel, France and Germany have also begun offering third vaccine doses to some people.

The World Health Organization has urged rich countries to stop administering booster doses until at least the end of the year, saying vaccines should immediately be redirected to Africa, where fewer than 4per cent of the population is fully immunized.

In a paper published last week in the journal Lancet, top scientists from the WHO and FDA argued that the average person doesn't need a booster shot and that the authorized vaccines to date provide strong protection against severe COVID-19, hospitalisation and death.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp